Working... Menu

Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00575939
Recruitment Status : Completed
First Posted : December 18, 2007
Last Update Posted : December 19, 2014
Bristol-Myers Squibb
Information provided by (Responsible Party):
Grace McComsey, University Hospitals Cleveland Medical Center

Brief Summary:
It is well known that HIV-infected subjects frequently experience hyperlipidemias, insulin resistance, and visceral adiposity, which are known to increase the risk of atherosclerosis. Several cohorts have shown an increased risk of heart disease in people with HIV. The effect of HIV treatment versus HIV itself on the incidence of heart disease is unclear. In this study the investigators will assess the effect on carotid IMT of the initiation of antiretroviral combinations that are known to have a minimal effect on lipids and insulin resistance. We will also assess the changes in several inflammation and cardiovascular markers,as well as endothelial activation markers,and how these changes relate to therapy-induced changes in immunologic, virologic and metabolic markers.

Condition or disease
HIV Infections Atherosclerosis

Layout table for study information
Study Type : Observational
Actual Enrollment : 120 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Assessment of the Use of a Metabolically-friendly Antiretroviral Regimen to Slow Down the Rate of Progression in Carotid Artery Intima-medial Thickness in Adults With HIV
Study Start Date : November 2007
Actual Primary Completion Date : July 2013
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

HIV positive
HIV infected treatment naive with CD4 cell count of at least 400
Healthy controls
Healthy controls

Primary Outcome Measures :
  1. Changes in Carotid IMT [ Time Frame: Annualy for 4 years ]

Secondary Outcome Measures :
  1. Increase or decrease in Inflammatory markers [ Time Frame: Annually for 4 years ]
  2. Changes in Fasting lipids [ Time Frame: Annually for 4 years ]
  3. Change in Insulin resistance by HOMA score [ Time Frame: Annually for 4 years ]

Biospecimen Retention:   Samples Without DNA
Stored plasma and serum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

80 HIV-infected adults older than 18 years of age, ART-naïve with CD4 count of at least 400 cells/mm3

The control group will be adults, healthy controls with no active infection or inflammatory condition, who are matched by gender and age to the HIV positive group


Inclusion Criteria for HIV positive group:

  • HIV-1 infection
  • Age at least 18 years
  • Naïve to antiretroviral therapy
  • CD4 cell count > 400 cells/mm3

For controls: Age at least 18 years, no known HIV infection, and no known medical condition requiring chronic use of prescription medications.

Exclusion Criteria (both groups):

  • Diabetes
  • Pregnant or breastfeeding
  • Women of child bearing age who refuse or are unable to use appropriate methods of contraception during the entire study period.
  • Active infectious or inflammatory condition
  • In jail or involuntarily incarcerated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00575939

Layout table for location information
United States, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Grace A McComsey, MD Case Western Reserve University and University Hospitals of Cleveland

Layout table for additonal information
Responsible Party: Grace McComsey, Professor of Pediatrics and Medicine, University Hospitals Cleveland Medical Center Identifier: NCT00575939     History of Changes
Other Study ID Numbers: AIDS 070711
First Posted: December 18, 2007    Key Record Dates
Last Update Posted: December 19, 2014
Last Verified: December 2014

Keywords provided by Grace McComsey, University Hospitals Cleveland Medical Center:
Treatment Naive

Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents